An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease-Reference-Cited by-同舟云学术

An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease

Published:2024-05 Issue:20 Volume:83 Page:1939-1952
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Koren Michael J.,Rodriguez Fatima^ORCID,East Cara,Toth Peter P.,Watwe Veena,Abbas Cheryl A.,Sarwat Samiha,Kleeman Kelly,Kumar Biswajit,Ali Yousuf,Jaffrani Naseem

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Reference35 articles.

1. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel;Ference;Eur Heart J,2017

2. Impact of lipids on cardiovascular health: JACC health promotion series;Ference;J Am Coll Cardiol,2018

3. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines;Grundy;Circulation. J Am Coll Cardiol,2019

4. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American College of Cardiology Solution Set Oversight Committee;Lloyd-Jones;J Am Coll Cardiol,2022

5. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS);Mach;Eur Heart J,2020

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-Coding RNA Involved in the Pathogenesis of Atherosclerosis—A Narrative Review;Diagnostics;2024-09-07

2. Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now?;Expert Review of Cardiovascular Therapy;2024-09

3. Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond;American Journal of Preventive Cardiology;2024-09

4. Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications;American Journal of Cardiovascular Drugs;2024-08-13

5. Sofortige Gabe von Incliseran mit beeindruckenden Ergebnissen (VICTORION-INITIATE);Aktuelle Kardiologie;2024-07-31